FDA Approves IMULDOSA (ustekinumab-srlf), Accord BioPharma's Biosimilar to STELARA (ustekinumab), for the Treatment of Chronic Inflammatory Conditions
PRNewswire Ahmedabad Gujarat [India] October 14 Accord BioPharma Inc the US specialty division of Intas Pharmaceuticals Ltd ...
Pharmabiz3d
Accord BioPharma receives US FDA approval for Imuldosa, a biosimilar to Stelara to treat chronic inflammatory conditions
Accord BioPharma receives US FDA approval for Imuldosa, a biosimilar to Stelara to treat chronic inflammatory conditions: Our Bureau, Mumbai Monday, October 14, 2024, 16:45 Hrs [I ...
devdiscourse3d
FDA Greenlights IMULDOSA: A Game-Changer in Biosimilar Treatments
Accord BioPharma has received FDA approval for IMULDOSA, a biosimilar to STELARA, for treating chronic inflammatory conditions like psoriasis and Crohn's disease. Scheduled for a 2025 launch, it aims ...
Managed Healthcare Executive2d
FDA Approves Imuldosa, the Fifth Stelara Biosimilar
Imuldose will be marketed in the United States by Accord BioPharma and is expected to launch in the first half of 2025.
Medscape1d
FDA Approves Fifth Ustekinumab Biosimilar
The drug is approved for multiple inflammatory conditions and is expected to launch in the first half of 2025.
Drug Store News1d
FDA approves Dong-A ST’s Stelara biosimilar
Imuldosa is used for the treatment of patients with autoimmune diseases such as plaque psoriasis, psoriatic arthritis, ...
US FDA Approves Dong-A ST’s IMULDOSA™ (ustekinumab-srlf), a Biosimilar to STELARA®
FDA approves the biologics license application (BLA) that Dong-A submitted in 2023 for Imuldosa, a biosimilar referencing ...